AstraZeneca strikes $1.5 billion AI drug discovery deal with Insitro
AstraZeneca $AZN announced a landmark agreement worth up to $1.5 billion with AI drug discovery platform Insitro to accelerate development of new pharmaceuticals. The partnership aims to leverage artificial intelligence to identify and develop novel compounds across multiple therapeutic areas.
The deal signals major pharmaceutical players' confidence in AI-driven discovery despite broader market concerns over AI spending and infrastructure valuations, positioning AstraZeneca to compete in next-generation drug development pipelines.
💬
No replies
Be the first to reply!